Company registration number 14743424 (England and Wales)
GCATBIO UK CO LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
GCATBIO UK CO LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
GCATBIO UK CO LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
31 December 2024
31 March 2024
Notes
£
£
£
£
Current assets
Debtors
3
-
0
1,000
Cash at bank and in hand
5,100
-
0
5,100
1,000
Creditors: amounts falling due within one year
4
(17,522)
-
0
Net current (liabilities)/assets
(12,422)
1,000
Capital and reserves
Called up share capital
1,000
1,000
Profit and loss reserves
(13,422)
-
0
Total equity
(12,422)
1,000

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements. true

The financial statements were approved and signed by the director and authorised for issue on 4 June 2026
Ms Y Shen
Director
Company registration number 14743424 (England and Wales)
GCATBIO UK CO LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

GCATBIO UK CO Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6th Floor, Manfield House, 1 Southampton Street, London, WC2R 0LR.

1.1
Reporting period

These financial statements are prepared for a period of shorter than one year in order to align its financial year with the group, therefore comparative amounts presented are not entirely comparable.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

The financial statements show net current liabilities of £12,422 and accumulated net losses of £13,422 which could indicate the company is not a going concern. true

The company started trading during the period and is still in the start up phase and therefore management expect the financial position to improve in future periods.

In considering the going concern status of the company the director has considered the availability of financing and support from its parent company and on this basis have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Sale of goods

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

GCATBIO UK CO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

GCATBIO UK CO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2024
2024
Number
Number
Total
0
0
3
Debtors
2024
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
-
0
1,000
4
Creditors: amounts falling due within one year
2024
2024
£
£
Amounts owed to group undertakings
3,770
-
0
Other creditors
13,752
-
0
17,522
-
0
5
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the period then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Nicholas Nicolaou FCCA
Statutory Auditor:
Alliotts LLP
Date of audit report:
4 June 2026
GCATBIO UK CO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 5 -
6
Related party transactions
2024
2024
Amounts due to related parties
£
£
Entities with control, joint control or significant influence over the company
3,770
-

The following amounts were outstanding at the reporting end date:

2024
2024
Amounts due from related parties
£
£
Entities with control, joint control or significant influence over the company
-
1,000
7
Parent company

The immediate parent company is GCATBIO Co Limited a company registered in Changzhou, China.

The ultimate parent company is BGI Shenzhen Technology Holding Group Co., Ltd. The ultimate controlling party is Jian Wang by virtue of their shareholding.

2024-12-31 2024-04-01 false false false 04 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Ms Y Shen 14743424 2024-04-01 2024-12-31 14743424 2024-12-31 14743424 2024-03-31 14743424 core:WithinOneYear 2024-12-31 14743424 core:WithinOneYear 2024-03-31 14743424 core:CurrentFinancialInstruments 2024-12-31 14743424 core:CurrentFinancialInstruments 2024-03-31 14743424 core:ShareCapital 2024-12-31 14743424 core:ShareCapital 2024-03-31 14743424 core:RetainedEarningsAccumulatedLosses 2024-12-31 14743424 core:RetainedEarningsAccumulatedLosses 2024-03-31 14743424 bus:Director1 2024-04-01 2024-12-31 14743424 2023-03-20 2024-03-31 14743424 core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity 2024-12-31 14743424 bus:PrivateLimitedCompanyLtd 2024-04-01 2024-12-31 14743424 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2024-12-31 14743424 bus:FRS102 2024-04-01 2024-12-31 14743424 bus:Audited 2024-04-01 2024-12-31 14743424 bus:FullAccounts 2024-04-01 2024-12-31 xbrli:pure xbrli:shares iso4217:GBP